Summary

Vascular Endothelial Growth Factor (VEGF) promotes ascites and effusions in ovarian cancer [Byrne AT et al. Clin Cancer Res 2003], and it is an independent adverse predictor of patient prognosis [Shen GH et al. Br J Cancer 2000]. Bevacizumab, a humanized monoclonal antibody that targets VEGF, has shown single-agent activity in Phase 2 epithelial ovarian cancer trials [Burger RA et al. N Engl J Med 2011]. This article provides an update on the data available from Phase 3 bevacizumab ovarian cancer trials.